Printer Friendly

NEORX INCREASES SIZE OF ITS BOARD OF DIRECTORS

 NEORX INCREASES SIZE OF ITS BOARD OF DIRECTORS
 SEATTLE, Nov. 26 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX)


announced today the appointment of David Blech and Mark S. Germain as corporate directors, expanding the company's board of directors from seven to nine. The appointments were made in connection with a sale of NeoRx securities to Blech in a private transaction.
 Since 1981, Blech has founded eight biotechnology companies. He is currently a director of Bio-Technology General Corp., Liposome Technology Inc., Envirogen, Inc., Ecogen Inc., Texas Biotechnology Corp., Neurogen Corp. and Pharmos Corp. In 1990, Blech formed D. Blech & Company, Inc., specializing in the formation and financing of lifesciences companies including healthcare, environmental and agricultural biotechnologies, and has invested in a number of other biotechnology companies. Germain is a managing director of D. Blech & Company and is currently a director of Bio-Technology General Corp., Ecogen, Inc., Ribi ImmunoChem Research, Inc., and Pharmos Corp.
 In making the announcement, Paul G. Abrams, NeoRx chief executive officer, said, "Messrs. Blech and Germain offer to NeoRx a great deal of experience in finance within the biotech industry. As NeoRx moves towards commercial development of its products, this expertise will become increasingly important in helping to see these products to fruition."
 NeoRx Corporation, incorporated in May 1984, is developing monoclonal antibody-based pharmaceutical products for in vivo detection and treatment of certain types of cancer. The company has three cancer therapy trials in progress and has filed for marketing approval with the Food and Drug Administration for two OncoTrac(R) imaging products to detect metastatic melanoma and small cell lung cancer.
 -0- 11/26/91
 /CONTACT: Robert M. Littauer, vice president, chief financial officer and treasurer of NeoRx, 206-286-2519; or Anthony J. Russo or Susan A. Noonan of Noonan/Russo Communications, 212-979-9180, for NeoRx/
 (NERX) CO: NeoRx Corporation ST: Washington IN: MTC SU: PER


GK-TS -- NY010 -- 7163 11/26/91 09:12 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 26, 1991
Words:314
Previous Article:NISSAN PROMOTES SAFE HOLIDAYS
Next Article:LOWE'S ANNOUNCES WEEKLY SALES
Topics:


Related Articles
NEORX ANNOUNCES FIRST QUARTER RESULTS FOR FISCAL 1992
LAWRENCE A. LOEB JOINS NEORX SCIENTIFIC ADVISORY BOARD
NEORX NAMES BIOTECHNOLOGY VETERAN FRED CRAVES CHAIRMAN OF BOARD OF DIRECTORS
NEORX DIVIDEND NOTICE
NEORX REPORTS FOURTH QUARTER 1995 RESULTS
NEORX DIVIDEND NOTICE
NeoRx Announces New Major Shareholder
NeoRx Closes $65 Million Financing Transaction.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters